Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued to investors on Monday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued reports about the company. JMP Securities restated a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Truist Financial cut Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. HC Wainwright reaffirmed a “neutral” rating and set a $2.00 price target on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $0.50 price target (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Nine investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of Marinus Pharmaceuticals stock opened at $0.31 on Monday. The stock has a market cap of $17.00 million, a P/E ratio of -0.12 and a beta of 1.26. The stock’s 50 day simple moving average is $1.22 and its 200-day simple moving average is $1.31. Marinus Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $11.26.

Institutional Trading of Marinus Pharmaceuticals

Large investors have recently modified their holdings of the business. Renaissance Technologies LLC acquired a new stake in Marinus Pharmaceuticals during the second quarter worth approximately $727,000. Vanguard Group Inc. boosted its position in Marinus Pharmaceuticals by 5.0% during the first quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock worth $25,366,000 after acquiring an additional 132,689 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in Marinus Pharmaceuticals during the second quarter worth approximately $813,000. Hussman Strategic Advisors Inc. boosted its position in Marinus Pharmaceuticals by 14.3% during the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 10,500 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in Marinus Pharmaceuticals during the second quarter worth approximately $206,000. 98.80% of the stock is currently owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.